Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H25NO4 |
| Molecular Weight | 391.4596 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@@H](OC(=O)C3=CC=CC=C3)C=C[C@]14CCN(C)CC5=CC=C(OC)C(O2)=C45
InChI
InChIKey=JKVNJTYHRABHIY-WXVUKLJWSA-N
InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1
| Molecular Formula | C24H25NO4 |
| Molecular Weight | 391.4596 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:32:57 UTC 2023
by
admin
on
Sat Dec 16 11:32:57 UTC 2023
|
| Record UNII |
XOI2Q0ZF7G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C188656
Created by
admin on Sat Dec 16 11:32:57 UTC 2023 , Edited by admin on Sat Dec 16 11:32:57 UTC 2023
|
PRIMARY | |||
|
300000042092
Created by
admin on Sat Dec 16 11:32:57 UTC 2023 , Edited by admin on Sat Dec 16 11:32:57 UTC 2023
|
PRIMARY | |||
|
44240142
Created by
admin on Sat Dec 16 11:32:57 UTC 2023 , Edited by admin on Sat Dec 16 11:32:57 UTC 2023
|
PRIMARY | |||
|
224169-27-1
Created by
admin on Sat Dec 16 11:32:57 UTC 2023 , Edited by admin on Sat Dec 16 11:32:57 UTC 2023
|
PRIMARY | |||
|
12069
Created by
admin on Sat Dec 16 11:32:57 UTC 2023 , Edited by admin on Sat Dec 16 11:32:57 UTC 2023
|
PRIMARY | |||
|
XOI2Q0ZF7G
Created by
admin on Sat Dec 16 11:32:57 UTC 2023 , Edited by admin on Sat Dec 16 11:32:57 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Galantos Pharma; Developer: Galantos Pharma, Neurodyn; Class Alkaloids: Benzazepine, Nootropic, Small molecule; Mechanism of Action: Acetylcholinesterase inhibitor, Nicotinic receptor modulator; Highest Development Phase: Phase I for Alzheimer's disease; Most Recent Events: 05 Mar 2016 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Netherlands (Intranasal) (NTR5678), 09 Sep 2014 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Canada prior to September 2014 (Intranasal), 09 Sep 2014 Efficacy, adverse events and pharmacokinetics data from a phase Ia trial in Alzheimer's disease (in volunteers) released by Neurodyn.
|